The downregulated genes in SIRT6-OE tumors significantly overlap with the proteomic signature upregulated in cells treated with entinostat, a histone deacetylase (HDAC) drug inhibitor used as breast cancer therapy68, confirming that this gene set is indeed regulated by histone acetylation in breast cancer (Fig. S10B). Here, HDAC9 is linked to breast carcinoma.